External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology AACR NCI EORTC 2023
Roche and Genentech at

AACR NCI EORTC 2023

October 11 - October 15
Boston USA
aacr.org/meeting/aacr-nci-eortc
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Oct 14 / Roche and Genentech
Efficacy and safety of entrectinib▼ in patients (pts) with locally advanced/metastatic NTRK or ROS1 fusion-positive (fp) solid tumors, not evaluable for the primary endpoint of STARTRK-2
Efficacy and safety of entrectinib▼ in patients who were not evaluable for the primary endpoint of the STARTRK-2 study, with a focus on patients who had non-measurable disease (by investigator) at baseline. The patient population in this analysis represents patients who are usually excluded from clinical trials.
Oncology Lung Cancer EORTC-NCI-AACR-2023
04:30 PM
Duration 3hrs Boston USA
Efficacy and safety of entrectinib▼ in patients (pts) with locally advanced/metastatic NTRK or ROS1 fusion-positive (fp) solid tumors, not evaluable for the primary endpoint of STARTRK-2
Liu S, Peeters M, Ahn M-J, Lin J, Ohe Y, Yau CCT, Bordogna W, Osbourne S, Schwemmers S, Zeuner H, Goto K
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.